Harbour BioMed inks $350 million deal for rights to A167
Member News
USA-based Harbour BioMed has entered into an exclusive strategic partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167
Related or similar articles
March 26, 2019
Abcuro announces pre-clinical data on new immuno-oncology target
First in vivo validation of KLRG1 as a new cancer immunotherapy target
Member News
August 19, 2019
Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Member News
March 8, 2024
Labshares Collaborates with Mispro and Charles River Accelerator and Development Lab (CRADL) to Create New Vivarium Partnerships
Exciting news at Labshares! We've partnered with Mispro and CRADL to enhance our shared lab spaces in Boston, offering members preferred pricing for top-notch research facilities.
Labshares News